Kyverna Therapeutics
Logotype for Kyverna Therapeutics Inc

Kyverna Therapeutics (KYTX) investor relations material

Kyverna Therapeutics Study update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kyverna Therapeutics Inc
Study update summary24 Sep, 2026

Study design and patient population

  • KYSA-8 is a single-arm, multicenter, open-label, phase II trial in Stiff Person Syndrome (SPS) with 26 patients who discontinued immunotherapies before miv-cel dosing.

  • KYSA-6 is a phase II trial in generalized Myasthenia Gravis (gMG) with seven patients who failed prior immunotherapies and stopped them before miv-cel treatment.

  • Both studies focus on patients with severe disease and high unmet needs who failed prior therapies.

  • Over 100 patients have been treated with miv-cel across autoimmune indications, showing consistent safety and efficacy.

Efficacy results in SPS (KYSA-8)

  • At one year, 95% of SPS patients maintained clinically meaningful improvement in the timed 25-ft walk test, with 24 of 26 remaining off immunotherapies.

  • Median walk time reduced by 49% from baseline at one year, with over one-third achieving healthy adult walking speed.

  • Statistically significant improvements were sustained across all primary and secondary endpoints at one year.

  • 67% of patients who previously needed walking aids walked unassisted at one year.

  • 92% of patients remained free of immunomodulatory or immunosuppressant therapies for SPS at one year.

Efficacy results in gMG (KYSA-6)

  • All seven gMG patients showed rapid and robust improvements in MG-ADL and QMG scores, sustained for at least one year.

  • Mean MG-ADL improvement was 8.2 points at 52 weeks; QMG improved by 12.8 points at 52 weeks.

  • 100% of patients achieved clinically meaningful responses in MG-ADL, QMG, and MGC; 57% sustained minimal symptom expression at last follow-up.

  • Nearly all patients remained off chronic immunotherapies, reducing treatment burden.

  • 86% of gMG patients remained off immunosuppressants at last follow-up.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Kyverna Therapeutics earnings date

Logotype for Kyverna Therapeutics Inc
Q3 202612 Nov, 2026
Kyverna Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Kyverna Therapeutics earnings date

Logotype for Kyverna Therapeutics Inc
Q3 202612 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Kyverna Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for autoimmune diseases. The company focuses on chimeric antigen receptor (CAR) T-cell therapies, which are designed to reset the immune system and potentially offer sustained treatment-free remission for patients. Kyverna’s main product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently in clinical trials for various autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, Kyverna is developing KYV-201, an allogeneic CAR T-cell therapy, and exploring treatments for other autoimmune diseases including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.